These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25700621)

  • 1. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
    Ogata K; Shimizu T; Masumoto H; Oguma T; Sugiyama N; Kunitada S
    Thromb Res; 2015 Apr; 135(4):594-601. PubMed ID: 25700621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
    Xuan D; McBride S; Wastall P; Porcari A; DiCarlo L; Boyd RA
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
    Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
    Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
    Kim J; Lee SH; Boyce M; Warrington S; Cho KH; Yoon SK; Park HD; Kim A
    Xenobiotica; 2015; 45(8):663-71. PubMed ID: 25673087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.
    Dixon-Jimenez AC; Brainard BM; Brooks MB; Nie B; Arnold RD; Loper D; Abrams JC; Rapoport GS
    J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):619-29. PubMed ID: 27599304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1041-50. PubMed ID: 27259709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
    Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
    J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
    Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
    Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
    Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.
    Graefe-Mody EU; Schühly U; Rathgen K; Stähle H; Leitner JM; Jilma B
    J Thromb Haemost; 2006 Jul; 4(7):1502-9. PubMed ID: 16839346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
    Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
    Frost C; Garonzik S; Shenker A; Barrett YC; LaCreta F
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
    Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
    Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.